Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 21;14(1):4314.
doi: 10.1038/s41598-024-54332-1.

Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB

Renata de Sá Brito Fróes  1 , Adriana Ribas Andrade  2 , Mikaell Alexandre Gouvea Faria  3 , Heitor Siffert Pereira de Souza  4 , Rogério Serafim Parra  5 , Cyrla Zaltman  4 , Carlos Henrique Marques Dos Santos  6 , Mauro Bafutto  7 , Abel Botelho Quaresma  8 , Genoile Oliveira Santana  2 , Rafael Luís Luporini  9 , Sérgio Figueiredo de Lima Junior  10 , Sender Jankiel Miszputen  11 , Mardem Machado de Souza  12 , Giedre Soares Prates Herrerias  13 , Roberto Luiz Kaiser Junior  3 , Catiane Rios do Nascimento  1 , Omar Féres  5 , Jaqueline Ribeiro de Barros  13 , Ligia Yukie Sassaki  14 , Rogerio Saad-Hossne  15
Affiliations

Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB

Renata de Sá Brito Fróes et al. Sci Rep. .

Abstract

The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) established a national registry of inflammatory bowel disease (IBD). The aim of the study was to identify clinical factors associated with disease severity in IBD patients in Brazil. A population-based risk model aimed at stratifying the severity of IBD based on previous hospitalization, use of biologics, and need for surgery for ulcerative colitis (UC) and Crohn's Disease (CD) and on previous complications for CD. A total of 1179 patients (34.4 ± 14.7y; females 59%) were included: 46.6% with UC, 44.2% with CD, and 0.9% with unclassified IBD (IBD-U). The time from the beginning of the symptoms to diagnosis was 3.85y. In CD, 41.2% of patients presented with ileocolic disease, 32% inflammatory behavior, and 15.5% perianal disease. In UC, 46.3% presented with extensive colitis. Regarding treatment, 68.1%, 67%, and 47.6% received biological therapy, salicylates and immunosuppressors, respectively. Severe disease was associated with the presence of extensive colitis, EIM, male, comorbidities, and familial history of colorectal cancer in patients with UC. The presence of Montreal B2 and B3 behaviors, colonic location, and EIM were associated with CD severity. In conclusion, disease severity was associated with younger age, greater disease extent, and the presence of rheumatic EIM.

Keywords: Crohn’s disease; Epidemiology; Inflammatory bowel disease; Registry; Severity; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Renata de Sá Brito Fróes—Received lecture fee[s] from AbbVie, Janssen, Takeda, Ferring and Pfizer; is advisory committee member for Janssen and Takeda; Adriana Ribas Andrade—Received lecture fee[s] from AbbVie, Janssen; Mikaell Alexandre Gouvea Faria—Received lecture fee[s] from AbbVie, Janssen, Takeda, Nestlé, advisory committee member for Janssen; Rogério Serafim Parra—Received lecture fee[s] from AbbVie, Janssen, Takeda, and Pfizer; is advisory committee member for Janssen and AbbVie; Cyrla Zaltman—Received lecture fee[s] from Janssen, Takeda, Celltrion, Pfizer; Carlos Henrique Marques dos Santos—Received lecture fee[s] from AbbVie, Janssen, Takeda; Mauro Bafutto—Received lecture fee[s] from AbbVie, Janssen, Takeda; Abel Botelho Quaresma—Received lecture fee[s] from AbbVie, Janssen; Genoile Oliveira Santana—Received lecture fee[s] from AbbVie, Janssen, Takeda, Ferring and Pfizer; is advisory committee member for Janssen; Rafael Luís Luporini—Received lecture fee[s] from AbbVie, Janssen, Takeda; Mardem Machado de Souza—Received lecture fee[s] from AbbVie, Janssen, Takeda; Ligia Yukie Sassaki—Received lecture fee[s] from Janssen; Rogerio Saad-Hossne—Received lecture fee[s] and advisory committee member for AbbVie, Takeda, Janssen, Pfizer, Fresenius and Amgen. Heitor Siffert Pereira de Souza, Sérgio Figueiredo de Lima Junior, Sender Jankiel Miszputen, Giedre Soares Prates Herrerias, Roberto Luiz Kaiser Junior, Catiane Rios do Nascimento, Omar Féres, Jaqueline Ribeiro de Barros—No potential conflict of interest to disclose.

Similar articles

See all similar articles

References

    1. Kaplan GG, Ng SC. Understanding and Preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313–321.e. doi: 10.1053/j.gastro.2016.10.020. - DOI - PubMed
    1. da Luz MA, de Campos Lobato LF, de Lima Moreira JP, Luiz RR, Elia C, Fiocchi C, de Souza HSP. Geosocial features and loss of biodiversity underlie variable rates of inflammatory bowel disease in a large developing country: A population-based study. Inflamm. Bowel Dis. 2022;28(11):1696–1708. doi: 10.1093/ibd/izab346. - DOI - PubMed
    1. Quaresma AB, Damiao AOMC, Coy CSR, Magro DO, Hino AAF, Valverde DA, Panaccione R, Coward SB, Ng SC, Kaplan GG, Kotze PG. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. Lancet Reg. Health Am. 2022;9(13):100298. doi: 10.1016/j.lana.2022.100298. - DOI - PMC - PubMed
    1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021;18(1):56–66. doi: 10.1038/s41575-020-00360-x. - DOI - PMC - PubMed
    1. Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: The incidence and prevalence of inflammatory bowel disease in Brazil. Curr. Opin. Gastroenterol. 2019;35(4):259–264. doi: 10.1097/MOG.0000000000000534. - DOI - PubMed